Two Markets, Two Classes of Investor
The Gains Are Booked Before the Bell Ever Rings
Consider the arc of an AI leader. OpenAI raised at a $852 billion valuation in a private round in March, up from a small fraction of that three years earlier. The investors in those rounds, venture funds, sovereign wealth funds, and a thin layer of accredited individuals, captured the move from startup to near-trillion-dollar company. That is the phase where the money is made. By the time OpenAI files to list, targeting September, the valuation range being discussed runs from $730 billion to more than $1 trillion. The public investor is invited to buy at the top of that range, after the private holders have already ridden it up.
This is not unique to OpenAI. Anthropic is targeting a $400 to $500 billion listing in October. The entire 2026 AI IPO wave, including SpaceX, Stripe, and Databricks candidates, could total $150 to $200 billion in raises. In every case, the steepest part of the value creation happened while the company was private, behind a legal wall that the ordinary investor is not permitted to cross.
The Rule That Draws the Line
The wall has a name: the accredited-investor standard. Under Regulation D, the exemption that governs most private placements, a company can sell shares privately only to investors who clear a financial bar, a net worth above $1 million excluding a primary residence, or income above $200,000 a year. The logic is protective. Private companies disclose far less than public ones, and the rule assumes that wealthier investors can either evaluate the risk or absorb the loss.
The effect, though, is exclusion. Roughly 87% of American households fall below the accredited threshold. The secondary marketplaces that trade private shares, Forge, EquityZen, Hiive, are open only to those who qualify. So the fastest-appreciating asset class of the decade has, by law, been reserved for the people who were already wealthy. The rule written to protect the small investor is the same rule that locks the small investor out of the gains.
Our view: this is a genuine cross-asset disagreement, just not the usual kind. It is not equities versus bonds. It is the private market versus the public market, and the variable that separates them is not price or yield. It is legal access. When one class of investor can buy the growth phase and another can only buy the mature phase, the two are not participating in the same market at all.
The Exceptions, and What They Cost
There are a few ways through the wall, and each has a catch. Publicly traded proxies, a listed venture firm that holds pre-IPO names, give indirect exposure but dilute it heavily. Tokenized IPO products and pre-IPO derivatives have appeared on some crypto platforms, but as the SEC and independent analysts note, a token backed by a custodian is not the same as owning the share, and a cash-settled derivative has no shares behind it at all. Voting rights and legal claims usually stay with the custodian, not the holder.
The one direct, SEC-sanctioned door for a non-accredited investor is Regulation A+, the framework often called the mini-IPO. Created by the JOBS Act and expanded in 2015, it lets a company raise up to $75 million a year from accredited and non-accredited investors alike through a qualified Form 1-A, a lighter process than a full S-1. It is the only path that lets an ordinary investor buy actual shares of a private company before it lists.
It is not a free lunch. The SEC’s own researchers found that of roughly $28 billion sought through Reg A+ since 2015, only about $9.4 billion actually closed, and most of those issuers still have no liquid secondary market. The illiquidity is real and the risk of total loss is real. But it is the one structure where the wall has a door rather than just a window, and for a non-accredited investor who wants direct pre-IPO ownership, it is effectively the only one.
The Read for the Ordinary Investor
The trading-desk discipline here is to see the structure clearly before chasing the story. The private AI names are extraordinary businesses, but the ordinary investor’s access to them is late, indirect, and usually at the mature valuation. That does not make private investing wrong. It makes it a place to apply more scrutiny, not less, because the disclosure is thinner and the liquidity is worse precisely where the marketing is loudest.
Worth watching: the SpaceX round-trip is the cautionary case study. A $1.5 trillion private mark became a public price near half that within weeks, which means even the accredited holders who bought the last private round were not guaranteed a win. The lesson is not that private is always better than public. It is that the two markets price the same company differently, they admit different investors, and a non-accredited investor considering a Reg A+ deal is trading illiquidity and thin disclosure for early access. That trade can be worth making. It should never be made without seeing exactly what is on both sides of it.
|
